Pharmaxis Ltd (AU:SNT) has released an update.
Syntara Limited has successfully completed enrollment for its Phase 2 trial of SNT-5055 for treating myelofibrosis, with no serious adverse reactions reported and a strong safety profile observed. The company anticipates presenting interim results in December 2024, which could lead to pivotal FDA discussions regarding the drug’s future. The drug, which has potential market implications exceeding $1 billion, has shown promise in prior trials and could significantly impact treatment for myelofibrosis and other cancers.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
